You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ELECTROFUSION AND ELECTROPERMEATION OF CELLS

    SBC: Electrocell            Topic: N/A

    THE TECHNIQUE OF ELECTROPORATION IS UTILIZED TO PERMEATE CELL MEMBRANES TO INTRODUCE DRUGS OR FOREIGN GENETIC MATERIALS INTO LIVING CELLS. ELECTROFUSION IS USED AS A NEWAPPROACH TO FORM HYBRID CELLS FOR GENETICS STUDIES AND FOR MONOCLONAL ANTIBODY PRODUCTION, AS WELL AS FOR DRUG INFUSIONVIA LIPOSOMES. ELECTROCELL PLANS TO DEVELOP PROTOCOLS FOR ELECTROPORATION AND ELECTROFUSION OF COMMON CELL TYPES ...

    SBIR Phase I 1987 Department of Health and Human Services
  2. Eltoprazine for the Treatment of Cognitive Dysfunction Assoc. With Schizophrenia

    SBC: PGI HOLDING CORPORATION            Topic: NIMH

    DESCRIPTION (provided by applicant): Schizophrenia is a common and highly disabling psychiatric disorder with a population prevalence around 1%. The manifestations of schizophrenia fall into three major domains: 1) positive symptoms; 2) negative symptoms: and 3) cognitive dysfunction. All marketed therapies for the treatment of Schizophrenia are antagonists or partial agonists of the D2 dopami ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Enabling use of blood spot cards for accurate high-throughput Fragile X screening

    SBC: ASURAGEN, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop accurate, rapid, high-throughput and cost-effective diagnostic tests for Fragile X syndrome (FXS) and related disorders in anticipation of population screening needs. Newborn screening (NBS) for Fragile X is timely due to the disease prevalence, lack of a clear phenotype at birth, current and emerging options for ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Engineering Escherichia coli for glycosylation of complex human proteins

    SBC: Glycobia, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Escherichia coli was the host organism for production of the first approved recombinant protein therapeutic in 1982. We now know that most therapeutic proteins require N-linked protein glycosylation to achieve their full clinical efficacy. Since E. coli has not been capable of protein glycosylation, the majority of approved therapeutic proteins are now expresse ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Enhanced Bioprocessing Strategies for Human Mesenchymal Stem Cells

    SBC: CELL PRESERVATION SERVICES INC            Topic: NCRR

    DESCRIPTION (provided by applicant): The results of early clinical trials using stem cells clearly offer the promise of a new path to addressing a variety of medical problems that range from creating engineered tissues for autologous grafts to repairing a variety of organs. Mesenchymal stem cells (MSCs) are especially attractive candidates for stem cell therapy given their documented character ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Enzymatic Detection of Petroleum in Seafood

    SBC: BIOO SCIENTIFIC CORPORATION            Topic: FDA

    DESCRIPTION (provided by applicant): Oil spills can cause tremendous environmental damage and are a serious threat to public health. Petroleum contains many toxic compounds such as polyaromatic hydrocarbons (PAHs). Some PAH compounds are highly carcinogenic and cause DNA mutations in humans. When petroleum is spilled into the sea, PAH compounds rapidly spread through the marine environment and eve ...

    SBIR Phase I 2011 Department of Health and Human ServicesFood and Drug Administration
  7. EXOSCOPE SYSTEM FOR LASER-WELDING BOWEL ANASTOMOSES

    SBC: Lasersurge Inc            Topic: N/A

    N/A

    SBIR Phase I 1987 Department of Health and Human Services
  8. EXPERT RADIOLOGY ASSISTANT

    SBC: Xdata Corp.            Topic: N/A

    FEASIBILITY RESEARCH IS PROPOSED FOR THE DEVELOPMENT OF A COMPUTER-BASED EXPERT RADIOLOGY ASSISTANT (XRA) TO AID IN THE DIAGNOSIS OF BREAST CANCER. THE PROPOSED EXPERT SYSTEM HAS THE POTENTIAL TO ASSIST RADIOLOGISTS IN THE INTERPRETATION OF DIAGNOSTIC IMAGES AND CLINICAL DATA USING ARTIFICIAL INTELLIGENCE. THE SYSTEM WAS FORMED BY ENCODING IN THE COMPUTER SOFTWARE THE KNOWLEDGE OF HUMAN EXPERTS. T ...

    SBIR Phase I 1987 Department of Health and Human Services
  9. Feasibility of Supercritical Carbon Dioxide Sterilization for Absorbable Suture M

    SBC: NOVASTERILIS, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Over the past several decades there has been relatively little innovation in the arena of medical device sterilization. Ethylene oxide (ETO) and gamma irradiation (3-irradiation) are the only technologies currently available for medical devices. In particular, synthetic polymeric medical devices are sterilized almost exclusively by ETO due to undesirable chemic ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. FIBER-DELIVERED ERBIUM: YAG LASER FOR ANGIOPLASTY

    SBC: Quantronix Corpon            Topic: N/A

    A COMMERCIAL MODEL OF AN OPTICALLY PUMPED, PULSED, ER:YAG SOLID-STATE LASER WILL BE MODIFIED AND TESTED FOR BEAM PERFORMANCE AND USED IN CONJUNCTION WITH A COMPATIBLE LOW-LOSS, FLEXIBLE NONTOXIC, FLUORIDE GLASS DELIVERY FIBER TO STUDY IN VITRO TUSSUE INTERACTION EFFECTS. THE LASER OPERATES AT AN APPROXIMATE WAVELENGTH OF 2.94 MUM ON THE 4I11/2-4I13/2 TRANSITION OF TRIVALENT ERBIUM. TISSUE INTERACT ...

    SBIR Phase I 1987 Department of Health and Human Services
US Flag An Official Website of the United States Government